Olema Pharmaceuticals (OLMA) Net Income towards Common Stockholders (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$53.2 million in Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$53.2 million, down 75.33% year-over-year; the trailing twelve-month figure through Mar 2026 was -$185.3 million (down 43.74% YoY), and the FY2025 annual result was -$162.5 million, down 25.39% from the prior year.
• Net Income towards Common Stockholders retreated to -$53.2 million in Q1 2026 per OLMA's latest filing, from -$46.1 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$20.1 million in Q2 2023 and troughed at -$53.2 million in Q1 2026.
• A 5-year average of -$32.2 million and a median of -$30.4 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders slumped 100.41% in 2022, then jumped 39.01% in 2023.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$26.2 million in 2022, then slipped by 2.36% to -$26.9 million in 2023, then fell by 24.6% to -$33.5 million in 2024, then tumbled by 37.64% to -$46.1 million in 2025, then fell by 15.49% to -$53.2 million in 2026.
• Business Quant data shows OLMA's Net Income towards Common Stockholders at -$53.2 million in Q1 2026, -$46.1 million in Q4 2025, and -$42.2 million in Q3 2025.